Biology of Blood and Marrow Transplantation
Volume 16, Issue 2 , Pages 157-168, February 2010

Hepatic Veno-Occlusive Disease following Stem Cell Transplantation: Incidence, Clinical Course, and Outcome

  • Jason A. Coppell

      Affiliations

    • Department of Haematology, Royal Devon and Exeter Hospital, Exeter, UK
    • The first two authors contributed equally to this manuscript.
    • Corresponding Author InformationCorrespondence and reprint requests: Jason A. Coppell, MA, MRCP, FRCPath, Haematology Centre, Level 1 Area B, Royal Devon and Exeter Hospital, Barrack Road, Exeter, Devon, UK, EX2 5DW.
  • ,
  • Paul G. Richardson

      Affiliations

    • Dana-Farber Cancer Institute, Boston, Massachusetts
    • The first two authors contributed equally to this manuscript.
    • Corresponding Author InformationPaul G. Richardson, MD, FRCP, Division of Hematologic Malignancy, Dana-Farber Cancer Institute, Harvard Medical School, D1B30, 44 Binney Street, Boston, MA 02115.
  • ,
  • Robert Soiffer

      Affiliations

    • Dana-Farber Cancer Institute, Boston, Massachusetts
  • ,
  • Paul L. Martin

      Affiliations

    • Duke University Medical Center, Durham, North Carolina
  • ,
  • Nancy A. Kernan

      Affiliations

    • Memorial Sloan-Kettering Cancer Center, New York, New York
  • ,
  • Allen Chen

      Affiliations

    • Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland
  • ,
  • Eva Guinan

      Affiliations

    • Dana-Farber Cancer Institute, Boston, Massachusetts
  • ,
  • Georgia Vogelsang

      Affiliations

    • Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland
  • ,
  • Amrita Krishnan

      Affiliations

    • City of Hope Cancer Center, Duarte, California
  • ,
  • Sergio Giralt

      Affiliations

    • Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, Texas
  • ,
  • Carolyn Revta

      Affiliations

    • Dana-Farber Cancer Institute, Boston, Massachusetts
  • ,
  • Nicole A. Carreau

      Affiliations

    • Dana-Farber Cancer Institute, Boston, Massachusetts
  • ,
  • Massimo Iacobelli

      Affiliations

    • Gentium SpA, Villa Guardia, Italy
  • ,
  • Enric Carreras

      Affiliations

    • Hospital Clinic, Barcelona, Spain
  • ,
  • Tapani Ruutu

      Affiliations

    • Helsinki University Central Hospital, Helsinki, Finland
  • ,
  • Tiziano Barbui

      Affiliations

    • Ospedali Riuniti, Bergamo, Italy
  • ,
  • Joseph H. Antin

      Affiliations

    • Dana-Farber Cancer Institute, Boston, Massachusetts
  • ,
  • Dietger Niederwieser

      Affiliations

    • University of Leipzig, Leipzig, Germany

Received 2 March 2009; accepted 21 August 2009. published online 09 October 2009.

The occurrence of hepatic veno-occlusive disease (VOD) has been reported in up to 60% of patients following stem cell transplantation (SCT), with incidence varying widely between studies depending on the type of transplant, conditioning regimen, and criteria used to make the diagnosis. Severe VOD is characterized by high mortality and progression to multiorgan failure (MOF); however, there is no consensus on how to evaluate severity. This review and analysis of published reports attempts to clarify these issues by calculating the overall mean incidence of VOD and mortality from severe VOD, examining the effect of changes in SCT practice on the incidence of VOD over time, and discussing the methods used to evaluate severity. Across 135 studies performed between 1979 and October 2007, the overall mean incidence of VOD was 13.7% (95% confidence interval [CI]=13.3%-14.1%). The mean incidence of VOD was significantly lower between 1979-1994 than between 1994-2007 (11.5% [95% CI, 10.9%-12.1%] vs 14.6% [95% CI, 14.0%-15.2%]; P <.05). The mortality rate from severe VOD was 84.3% (95% CI, 79.6%-88.9%); most of these patients had MOF, which also was the most frequent cause of death. Thus, VOD is less common than early reports suggested, but the current incidence appears to be relatively stable despite recent advances in SCT, including the advent of reduced-intensity conditioning. The evolution of MOF in the setting of VOD after SCT can be considered a reliable indication of severity and a predictor of poor outcome.

Key Words: Veno-occlusive disease, Stem cell transplantation, Incidence, Outcome, Severity, Multiorgan failure

 

 Financial disclosure: See Acknowledgments on page 164.

PII: S1083-8791(09)00418-2

doi:10.1016/j.bbmt.2009.08.024

Biology of Blood and Marrow Transplantation
Volume 16, Issue 2 , Pages 157-168, February 2010